<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792073</url>
  </required_header>
  <id_info>
    <org_study_id>20-195</org_study_id>
    <nct_id>NCT04792073</nct_id>
  </id_info>
  <brief_title>Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma</brief_title>
  <official_title>A Phase II Randomized, Parallel Two-Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy With or Without Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the use of comprehensive ablative radiation therapy (CART), with and&#xD;
      without the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has&#xD;
      progressed after treatment and cannot be removed with surgery. The study researchers want to&#xD;
      find out whether CART works better when is given with avelumab than it does when given alone&#xD;
      to prevent the cancer from getting worse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, open-label, single-center, phase II randomized parallel two-arm clinical trial of comprehensive ablative radiation therapy (CART) with or without avelumab for patients with metastatic or unresectable Merkel cell carcinoma (MCC).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>measured by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>measured by RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Avelumab and Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive avelumab at the FDA approved dose and schedule of 800 mg IV over 60 minutes every 2 weeks (+/- 3 days) until treatment intolerance or disease progression occurs.Comprehensive Ablative Radiation Therapy (CART) will be initiated between the first and second dose of avelumab. Comprehensive ablative radiation therapy will be given according to guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive Comprehensive Ablative Radiation Therapy (CART) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab 800 mg given intravenously over 60 minutes every 2 weeks (+/- 3 days)</description>
    <arm_group_label>Avelumab and Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Comprehensive Ablative Radiation Therapy</intervention_name>
    <description>Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days</description>
    <arm_group_label>Avelumab and Radiation Therapy</arm_group_label>
    <arm_group_label>Radiation Therapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven Merkel cell carcinoma which is unresectable or metastatic, stage III or&#xD;
             IV&#xD;
&#xD;
          -  Prior first-line treatment with aPD1 monotherapy (defined as at least one dose of&#xD;
             pembrolizumab, avelumab, nivolumab, etc.) with evidence of progression of disease ≥10&#xD;
             weeks after starting therapy, in the absence of significant clinical deterioration&#xD;
&#xD;
               -  Patients with progression in only one of several responding metastases will not&#xD;
                  be eligible&#xD;
&#xD;
               -  Patients with clinical deterioration during aPD1 monotherapy are eligible ≥6&#xD;
                  weeks after starting aPD1 therapy&#xD;
&#xD;
               -  Criteria for clinical deterioration to be determined and agreed upon by treating&#xD;
                  physician and Principal Investigator&#xD;
&#xD;
          -  All detectable sites of MCC are amenable to comprehensive ablative radiation therapy&#xD;
             in opinion of treating radiation oncologist and principal investigator&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Performance status ≤2 on the Eastern Cooperative Oncology Group Performance Scale&#xD;
&#xD;
          -  Able to provide valid written informed consent&#xD;
&#xD;
          -  Normal organ and marrow function&#xD;
&#xD;
               -  Hematologic: Lymphocyte count ≥800/mm^3, neutrophil count ≥1500/mm^3, platelet&#xD;
                  count ≥75,000/mm^3, leukocyte count ≥3000/mm^3, hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Hepatic: Total bilirubin ≤ 1.5 times the upper limit of normal, unless Gilbert's&#xD;
                  syndrome; aspartate transaminase and alanine transaminase ≤ 2.5 times the upper&#xD;
                  limit of normal (in the absence of hepatobiliary metastases); ≤ 3.0 times the&#xD;
                  upper limit of normal (in the presence of hepatobiliary metastases)&#xD;
&#xD;
               -  Renal: Estimated creatinine clearance ≥ 30 mL/min according to the&#xD;
                  Cockcroft-Gault formula.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for MCC other than first-line aPD1 monotherapy (ie,&#xD;
             chemotherapy)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Adverse events due to prior cancer therapy which are grade 3 or higher and have not&#xD;
             resolved&#xD;
&#xD;
             °Patients with prior grade 3 or higher immune related adverse events are not eligible,&#xD;
             even if they have resolved&#xD;
&#xD;
          -  Prior severe hypersensitivity reaction (CTCAE version 5.0 grade ≥3) to avelumab&#xD;
&#xD;
          -  Prior radiotherapy which precludes the ability to safely deliver comprehensive&#xD;
             ablative radiation therapy in the opinion of the treating radiation oncologist and&#xD;
             principal investigator&#xD;
&#xD;
             °Institutional guidelines for reirradiation will be used when making this&#xD;
             determination&#xD;
&#xD;
          -  Known central nervous system metastases&#xD;
&#xD;
          -  Known clinically significant cardiovascular disease, defined as:&#xD;
&#xD;
               -  Stroke or myocardial infarction within 6 months of first dose of avelumab&#xD;
&#xD;
               -  Symptomatic congestive heart failure (New York Heart Association Class 2 or&#xD;
                  higher)&#xD;
&#xD;
               -  Serious arrhythmia requiring anti-arrhythmic agents&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus infection&#xD;
&#xD;
          -  Known Hepatitis B or C infection requiring ongoing treatment&#xD;
&#xD;
          -  Vaccination within 4 weeks of first dose of avelumab&#xD;
&#xD;
             °Inactivated vaccines are permissible&#xD;
&#xD;
          -  Iatrogenic immunosuppression with daily systemic corticosteroid equivalent of &gt;10 mg&#xD;
             of prednisone&#xD;
&#xD;
          -  Active autoimmune disease that may cause clinical deterioration during immunotherapy&#xD;
&#xD;
             °Including, but not limited to:&#xD;
&#xD;
          -  Inflammatory bowel disease or immune colitis&#xD;
&#xD;
          -  Immune mediated pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  History of solid organ or hematopoietic transplant&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Active suicidal ideation or behavior&#xD;
&#xD;
          -  Comorbid or diagnostic abnormalities which would interfere with interpretation of&#xD;
             study results&#xD;
&#xD;
          -  Known hematopoietic cancer or dysfunction (i.e., leukemia, lymphoma)&#xD;
&#xD;
          -  Known non-MCC solid tumor with known metastasis or estimated risk of metastasis &gt;20%&#xD;
             within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoper Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoper Barker, MD</last_name>
    <phone>212-639-8168</phone>
    <email>barkerc@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra D'Angelo, MD</last_name>
    <phone>646-888-4159</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge (All Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (All Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (All Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Barker, MD</last_name>
      <phone>212-639-8168</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable</keyword>
  <keyword>metastatic</keyword>
  <keyword>stage III</keyword>
  <keyword>stage IV</keyword>
  <keyword>Comprehensive Ablative Radiation Therapy</keyword>
  <keyword>Avelumab</keyword>
  <keyword>20-195</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

